The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Advances in G Protein-Coupled Receptor Allostery: From Function to Structure
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationEmerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Self-citationChristopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486
Inhibition of oxytocin receptor function by direct binding of progesterone
Grazzini, E., Guillon, G., Mouillac, B., & Zingg, H. H. (1998) · Nature · doi:10.1038/33176 · Cited by 466
A surface on the androgen receptor that allosterically regulates coactivator binding
Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708036104 · Cited by 307
Research works printed but not linked: 178
- Abdul-Ridha, 2013, Allosteric modulation of a chemogenetically modified G protein-coupled receptor, Mol Pharmacol, 83, 521, 10.1124/mol.112.083006 · DOI
- Abdul-Ridha, 2014, Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor, J Biol Chem, 289, 6067, 10.1074/jbc.M113.539080 · DOI
- Ahn, 2012, Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation, J Biol Chem, 287, 12070, 10.1074/jbc.M111.316463 · DOI
- Allison, 2012, Reinventing clinical trials, Nat Biotechnol, 30, 41, 10.1038/nbt.2083 · DOI
- Antony, 2009, Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity, FASEB J, 23, 442, 10.1096/fj.08-114751 · DOI
- Aurelio, 2009, Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes, J Med Chem, 52, 4543, 10.1021/jm9002582 · DOI
- Avlani, 2010, Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor, Mol Pharmacol, 78, 94, 10.1124/mol.110.064345 · DOI
- Bauer, 2012, Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors, J Biol Chem, 287, 36944, 10.1074/jbc.M112.382481 · DOI · Paper page
- Black, 1983, Operational models of pharmacological agonism, Proc R Soc Lond B Biol Sci, 220, 141, 10.1098/rspb.1983.0093 · DOI · Paper page
- Block, 2004, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N Engl J Med, 350, 1516, 10.1056/NEJMoa031633 · DOI · Paper page
- Bock, 2012, The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling, Nat Commun, 3, 1044, 10.1038/ncomms2028 · DOI
- Bodick, 1997, The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease, Alzheimer Dis Assoc Disord, 11, S16
- Bono, 2013, Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties, Cancer Cell, 23, 477, 10.1016/j.ccr.2013.02.019 · DOI
- Borda, 1996, Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren’s syndrome, Mol Cell Biochem, 163-164, 335, 10.1007/BF00408674 · doi:10.1007/bf00408674
- Bradley, 2011, Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia, Mol Pharmacol, 79, 874, 10.1124/mol.110.068882 · DOI
- Braestrup, 1979, Partial agonists for brain GABA/benzodiazepine receptor complex, Nature, 280, 331, 10.1038/280331a0 · DOI
- Broadhead, 2011, Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with l-amino acids, J Biol Chem, 286, 8786, 10.1074/jbc.M110.149724 · DOI
- Bruns, 1990, Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes, Mol Pharmacol, 38, 939, 10.1016/S0026-895X(25)09591-4 · DOI · Paper page
- Busque, 2005, l-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells, Am J Physiol Gastrointest Liver Physiol, 289, G664, 10.1152/ajpgi.00096.2005 · DOI
- Canals, 2012, A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation, J Biol Chem, 287, 650, 10.1074/jbc.M111.314278 · DOI
- Canals, 2011, Allostery in GPCRs: ‘MWC’ revisited, Trends Biochem Sci, 36, 663, 10.1016/j.tibs.2011.08.005 · DOI
- Catterall, 2007, Voltage-gated ion channels and gating modifier toxins, Toxicon, 49, 124, 10.1016/j.toxicon.2006.09.022 · DOI · Paper page
- Chan, 2008, Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia, Proc Natl Acad Sci USA, 105, 10978, 10.1073/pnas.0800567105 · DOI · Paper page
- Changeux, 2013, 50 years of allosteric interactions: the twists and turns of the models, Nat Rev Mol Cell Biol, 14, 819, 10.1038/nrm3695 · DOI · Paper page
- Cherezov, 2007, High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor, Science, 318, 1258, 10.1126/science.1150577 · DOI · Paper page
- Christopoulos, 2002, Allosteric binding sites on cell-surface receptors: novel targets for drug discovery, Nat Rev Drug Discov, 1, 198, 10.1038/nrd746 · DOI · Paper page
- Christopoulos, 2014, International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands, Pharmacol Rev, 66, 918, 10.1124/pr.114.008862 · DOI · Paper page
- Christopoulos, 2003, Novel receptor partners and function of receptor activity-modifying proteins, J Biol Chem, 278, 3293, 10.1074/jbc.C200629200 · DOI · Paper page
- Christopoulos, 2002, G protein-coupled receptor allosterism and complexing, Pharmacol Rev, 54, 323, 10.1124/pr.54.2.323 · DOI · Paper page
- Clark, 1976, The inhibitory effect of gallamine on muscarinic receptors, Br J Pharmacol, 58, 323, 10.1111/j.1476-5381.1976.tb07708.x · DOI · Paper page
- Ciolek, 2011, Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor, Eur J Pharmacol, 655, 1, 10.1016/j.ejphar.2010.12.042 · doi:10.1016/j.ejphar.2010.12.042
- Colquhoun, 1998, Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors, Br J Pharmacol, 125, 924, 10.1038/sj.bjp.0702164 · DOI · Paper page
- Conigrave, 2010, Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development, Pharmacol Ther, 127, 252, 10.1016/j.pharmthera.2010.04.007 · DOI
- Conigrave, 2000, l-amino acid sensing by the extracellular Ca2+-sensing receptor, Proc Natl Acad Sci USA, 97, 4814, 10.1073/pnas.97.9.4814 · DOI · Paper page
- Coureuil, 2010, Meningococcus hijacks a β2-adrenoceptor/β-arrestin pathway to cross brain microvasculature endothelium, Cell, 143, 1149, 10.1016/j.cell.2010.11.035 · DOI · Paper page
- Davey, 2012, Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor, Endocrinology, 153, 1232, 10.1210/en.2011-1426 · DOI · Paper page
- De Lean, 1980, A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor, J Biol Chem, 255, 7108, 10.1016/S0021-9258(20)79672-9 · DOI · Paper page
- De Smet F, Christopoulos A, Carmeliet P (2014) Allosteric targeting of receptor tyrosine kinases. Nat Biotechnol, in press. · DOI
- Disingrini, 2006, Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors, J Med Chem, 49, 366, 10.1021/jm050769s · DOI
- Dror, 2013, Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs, Nature, 503, 295, 10.1038/nature12595 · DOI · Paper page
- Ehlert, 1985, The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium, Mol Pharmacol, 28, 410, 10.1016/S0026-895X(25)14182-5 · DOI · Paper page
- Ehlert, 1982, Modulation of benzodiazepine receptor binding: insight into pharmacological efficacy, Eur J Pharmacol, 78, 249, 10.1016/0014-2999(82)90246-1 · doi:10.1016/0014-2999(82)90246-1
- Ehlert, 2005, Analysis of allosterism in functional assays, J Pharmacol Exp Ther, 315, 740, 10.1124/jpet.105.090886 · DOI · Paper page
- Ellis, 1992, Two allosteric modulators interact at a common site on cardiac muscarinic receptors, Mol Pharmacol, 42, 638, 10.1016/S0026-895X(25)09006-6 · doi:10.1016/s0026-895x(25)09006-6
- Eroglu, 2003, Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts, Proc Natl Acad Sci USA, 100, 10219, 10.1073/pnas.1737042100 · DOI
- Evans, 2011, Quantification of functional selectivity at the human α(1A)-adrenoceptor, Mol Pharmacol, 79, 298, 10.1124/mol.110.067454 · DOI
- Fenalti, 2014, Molecular control of δ-opioid receptor signalling, Nature, 506, 191, 10.1038/nature12944 · DOI · Paper page
- Fenton, 2008, Allostery: an illustrated definition for the ‘second secret of life’, Trends Biochem Sci, 33, 420, 10.1016/j.tibs.2008.05.009 · DOI · Paper page
- Ferré, 2014, G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives, Pharmacol Rev, 66, 413, 10.1124/pr.113.008052 · DOI · Paper page
- Figueroa, 2009, Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes, J Pharmacol Exp Ther, 328, 331, 10.1124/jpet.108.145219 · DOI
- Fillion, 1996, A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors, Behav Brain Res, 73, 313, 10.1016/0166-4328(96)00120-9 · doi:10.1016/0166-4328(96)00120-9
- Galvez, 2000, Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit, Mol Pharmacol, 57, 419, 10.1016/S0026-895X(24)26405-1 · doi:10.1016/s0026-895x(24)26405-1
- Gimpl, 1997, Cholesterol as modulator of receptor function, Biochemistry, 36, 10959, 10.1021/bi963138w · DOI · Paper page
- Goupil, 2010, A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2α-mediated Rho/ROCK signaling pathway, J Biol Chem, 285, 25624, 10.1074/jbc.M110.115196 · DOI
- Gregory, 2010, Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias, J Biol Chem, 285, 7459, 10.1074/jbc.M109.094011 · DOI · Paper page
- Gregory, 2012, Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships, Mol Pharmacol, 82, 860, 10.1124/mol.112.080531 · DOI
- Gurevich, 1997, Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity, J Biol Chem, 272, 28849, 10.1074/jbc.272.46.28849 · DOI · Paper page
- Haga, 2012, Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist, Nature, 482, 547, 10.1038/nature10753 · DOI · Paper page
- Hanson, 2008, A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor, Structure, 16, 897, 10.1016/j.str.2008.05.001 · DOI · Paper page
- Hedlund, 1999, Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors, Biochem Pharmacol, 58, 1807, 10.1016/S0006-2952(99)00274-9 · DOI
- Hernández, 2003, Human chagasic IgGs bind to cardiac muscarinic receptors and impair L-type Ca2+ currents, Cardiovasc Res, 58, 55, 10.1016/S0008-6363(02)00811-8 · DOI
- Hollenstein, 2013, Structure of class B GPCR corticotropin-releasing factor receptor 1, Nature, 499, 438, 10.1038/nature12357 · DOI · Paper page
- Holst, 2002, Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors, J Biol Chem, 277, 47662, 10.1074/jbc.M202103200 · DOI
- Huynh, 2013, Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor, J Med Chem, 56, 8196, 10.1021/jm401032k · DOI
- Jacobson, 2010, The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site, Mol Pharmacol, 78, 648, 10.1124/mol.110.065771 · doi:10.1124/mol.110.065771
- Jacoby, 1993, Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor, J Clin Invest, 91, 1314, 10.1172/JCI116331 · DOI · Paper page
- Katritch, 2014, Allosteric sodium in class A GPCR signaling, Trends Biochem Sci, 39, 233, 10.1016/j.tibs.2014.03.002 · DOI · Paper page
- Kebig, 2009, An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators, J Recept Signal Transduct Res, 29, 140, 10.1080/10799890903047437 · DOI
- Kenakin, 2005, New concepts in drug discovery: collateral efficacy and permissive antagonism, Nat Rev Drug Discov, 4, 919, 10.1038/nrd1875 · DOI · Paper page
- Kenakin, 2013, Signalling bias in new drug discovery: detection, quantification and therapeutic impact, Nat Rev Drug Discov, 12, 205, 10.1038/nrd3954 · DOI · Paper page
- Kenakin, 2010, Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery, Pharmacol Rev, 62, 265, 10.1124/pr.108.000992 · DOI · Paper page
- Kenakin, 2012, A simple method for quantifying functional selectivity and agonist bias, ACS Chem Neurosci, 3, 193, 10.1021/cn200111m · DOI · Paper page
- Keov, 2011, Allosteric modulation of G protein-coupled receptors: a pharmacological perspective, Neuropharmacology, 60, 24, 10.1016/j.neuropharm.2010.07.010 · DOI · Paper page
- Keov, 2013, Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor, Mol Pharmacol, 84, 425, 10.1124/mol.113.087320 · DOI
- Kerr, 2003, Potentiation of metabotropic GABAB receptors by L-amino acids and dipeptides in rat neocortex, Eur J Pharmacol, 468, 103, 10.1016/S0014-2999(03)01675-3 · doi:10.1016/s0014-2999(03)01675-3
- Koole, 2012, Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function, J Biol Chem, 287, 3659, 10.1074/jbc.M111.309369 · DOI
- Koole, 2010, Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening, Mol Pharmacol, 78, 456, 10.1124/mol.110.065664 · DOI · Paper page
- Koshland, 1966, Comparison of experimental binding data and theoretical models in proteins containing subunits, Biochemistry, 5, 365, 10.1021/bi00865a047 · DOI · Paper page
- Kruse, 2014, Muscarinic acetylcholine receptors: novel opportunities for drug development, Nat Rev Drug Discov, 13, 549, 10.1038/nrd4295 · DOI · Paper page
- Kruse, 2013, Activation and allosteric modulation of a muscarinic acetylcholine receptor, Nature, 504, 101, 10.1038/nature12735 · DOI · Paper page
- Lagerström, 2008, Structural diversity of G protein-coupled receptors and significance for drug discovery, Nat Rev Drug Discov, 7, 339, 10.1038/nrd2518 · DOI · Paper page
- Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, Lopez L, Scammells PJ, Capuano B, et al. (2014) A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol, in press. · DOI
- Lane, 2013, Bridging the gap: bitopic ligands of G-protein-coupled receptors, Trends Pharmacol Sci, 34, 59, 10.1016/j.tips.2012.10.003 · DOI · Paper page
- Langmead, 2008, Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1, Br J Pharmacol, 154, 1104, 10.1038/bjp.2008.152 · DOI
- Langmead, 2006, Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox, Trends Pharmacol Sci, 27, 475, 10.1016/j.tips.2006.07.009 · DOI
- Langmead, 2014, Functional and structural perspectives on allosteric modulation of GPCRs, Curr Opin Cell Biol, 27, 94, 10.1016/j.ceb.2013.11.007 · DOI
- Lazareno, 2004, Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity, Mol Pharmacol, 65, 257, 10.1124/mol.65.1.257 · DOI
- Leach, 2010, Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties, Neuropsychopharmacology, 35, 855, 10.1038/npp.2009.194 · DOI · Paper page
- Leach, 2007, Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology, Trends Pharmacol Sci, 28, 382, 10.1016/j.tips.2007.06.004 · DOI · Paper page
- Leach, 2012, Structure-function studies of muscarinic acetylcholine receptors, Handb Exp Pharmacol, 208, 29, 10.1007/978-3-642-23274-9_2 · DOI
- Leach, 2013, Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators, Endocrinology, 154, 1105, 10.1210/en.2012-1887 · DOI
- Leggett, 2004, Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors, Br J Pharmacol, 141, 253, 10.1038/sj.bjp.0705607 · DOI · Paper page
- Leiros, 1997, Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas’ disease, J Biol Chem, 272, 12989, 10.1074/jbc.272.20.12989 · doi:10.1074/jbc.272.20.12989
- Liou, 2011, The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to l-phenylalanine in acutely isolated intestinal I cells, Am J Physiol Gastrointest Liver Physiol, 300, G538, 10.1152/ajpgi.00342.2010 · DOI · Paper page
- Litschig, 1999, CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding, Mol Pharmacol, 55, 453, 10.1016/S0026-895X(24)12169-4 · DOI · Paper page
- Liu, 2012, Structural basis for allosteric regulation of GPCRs by sodium ions, Science, 337, 232, 10.1126/science.1219218 · DOI · Paper page
- Lüllmann, 1969, Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds, Eur J Pharmacol, 6, 241, 10.1016/0014-2999(69)90181-2 · DOI
- Ma, 2009, Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation, Proc Natl Acad Sci USA, 106, 15950, 10.1073/pnas.0900903106 · DOI · Paper page
- Maillet, 2007, A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties, FASEB J, 21, 2124, 10.1096/fj.06-7683com · doi:10.1096/fj.06-7683com
- Makita, 2007, An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations, Proc Natl Acad Sci USA, 104, 5443, 10.1073/pnas.0701290104 · DOI
- Marlo, 2009, Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity, Mol Pharmacol, 75, 577, 10.1124/mol.108.052886 · DOI
- Mary, 2012, Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor, Proc Natl Acad Sci USA, 109, 8304, 10.1073/pnas.1119881109 · DOI
- Massot, 1996, 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors, Mol Pharmacol, 50, 752, 10.1016/S0026-895X(25)09375-7 · DOI
- Mathiesen, 2005, Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2, Mol Pharmacol, 68, 393, 10.1124/mol.104.010520 · DOI
- May, 2007, Allosteric modulation of G protein-coupled receptors, Annu Rev Pharmacol Toxicol, 47, 1, 10.1146/annurev.pharmtox.47.120505.105159 · DOI · Paper page
- Melancon, 2012, Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery, J Med Chem, 55, 1445, 10.1021/jm201139r · DOI · Paper page
- Mistry, 2013, Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor, J Med Chem, 56, 5151, 10.1021/jm400540b · DOI
- Mohr, 2013, Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors, Angew Chem Int Ed Engl, 52, 508, 10.1002/anie.201205315 · DOI
- Mohr, 2010, Rational design of dualsteric GPCR ligands: quests and promise, Br J Pharmacol, 159, 997, 10.1111/j.1476-5381.2009.00601.x · DOI
- Monod, 1963, Allosteric proteins and cellular control systems, J Mol Biol, 6, 306, 10.1016/S0022-2836(63)80091-1 · DOI · Paper page
- Monod, 1965, On the nature of allosteric transitions: a plausible model, J Mol Biol, 12, 88, 10.1016/S0022-2836(65)80285-6 · DOI · Paper page
- Narlawar, 2010, Hybrid ortho/allosteric ligands for the adenosine A(1) receptor, J Med Chem, 53, 3028, 10.1021/jm901252a · DOI
- Nawaratne, 2010, Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms, J Biol Chem, 285, 19012, 10.1074/jbc.M110.125096 · DOI
- Neubig, 2003, International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology, Pharmacol Rev, 55, 597, 10.1124/pr.55.4.4 · DOI · Paper page
- Nussinov, 2013, Allostery in disease and in drug discovery, Cell, 153, 293, 10.1016/j.cell.2013.03.034 · DOI · Paper page
- Olsen, 2004, Fishing for allosteric sites on GABA(A) receptors, Biochem Pharmacol, 68, 1675, 10.1016/j.bcp.2004.07.026 · DOI
- Onaran, 2012, Where have all the active receptor states gone?, Nat Chem Biol, 8, 674, 10.1038/nchembio.1024 · doi:10.1038/nchembio.1024
- Pamplona, 2012, Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor, Proc Natl Acad Sci USA, 109, 21134, 10.1073/pnas.1202906109 · DOI · Paper page
- Parmentier-Batteur, 2014, Mechanism based neurotoxicity of mGlu5 positive allosteric modulators—development challenges for a promising novel antipsychotic target, Neuropharmacology, 82, 161, 10.1016/j.neuropharm.2012.12.003 · DOI
- Pasternak, 1975, Selective enhancement of [3H]opiate agonist binding by divalent cations, Mol Pharmacol, 11, 735, 10.1016/S0026-895X(25)10670-6 · doi:10.1016/s0026-895x(25)10670-6
- Pert, 1973, Opiate agonists and antagonists discriminated by receptor binding in brain, Science, 182, 1359, 10.1126/science.182.4119.1359 · DOI · Paper page
- Potter, 2012, Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol, J Lipid Res, 53, 137, 10.1194/jlr.M020065 · DOI
- Prasad, 2009, Membrane cholesterol depletion enhances ligand binding function of human serotonin1A receptors in neuronal cells, Biochem Biophys Res Commun, 390, 93, 10.1016/j.bbrc.2009.09.072 · DOI
- Price, 2005, Allosteric modulation of the cannabinoid CB1 receptor, Mol Pharmacol, 68, 1484, 10.1124/mol.105.016162 · DOI · Paper page
- Rajagopal, 2011, Quantifying ligand bias at seven-transmembrane receptors, Mol Pharmacol, 80, 367, 10.1124/mol.111.072801 · DOI · Paper page
- Reiter, 2012, Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors, Annu Rev Pharmacol Toxicol, 52, 179, 10.1146/annurev.pharmtox.010909.105800 · DOI · Paper page
- Rodriguez, 1992, Differential effects of Mg2+ and other divalent cations on the binding of tritiated opioid ligands, J Neurochem, 59, 467, 10.1111/j.1471-4159.1992.tb09393.x · DOI
- Rominger, 2009, Evidence for allosteric interactions of antagonist binding to the smoothened receptor, J Pharmacol Exp Ther, 329, 995, 10.1124/jpet.109.152090 · DOI
- Rosenbaum, 2011, Structure and function of an irreversible agonist-β(2) adrenoceptor complex, Nature, 469, 236, 10.1038/nature09665 · DOI · Paper page
- Rousselle, 1996, Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes, J Biol Chem, 271, 726, 10.1074/jbc.271.2.726 · DOI
- Schetz, 1997, Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors, J Neurochem, 68, 1990, 10.1046/j.1471-4159.1997.68051990.x · doi:10.1046/j.1471-4159.1997.68051990.x
- Schetz, 2001, The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation, J Pharmacol Exp Ther, 296, 359, 10.1016/S0022-3565(24)38793-2 · doi:10.1016/s0022-3565(24)38793-2
- Shirey, 2009, A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning, J Neurosci, 29, 14271, 10.1523/JNEUROSCI.3930-09.2009 · DOI · Paper page
- Shonberg, 2013, A structure-activity analysis of biased agonism at the dopamine D2 receptor, J Med Chem, 56, 9199, 10.1021/jm401318w · DOI
- Shonberg J, Lopez L, Scammells PJ, Christopoulos A, Capuano B, Lane JR (2014) Biased agonism at G protein-coupled receptors: the promise and the challenges—a medicinal chemistry perspective. Med Res Rev. DOI: 10.1002/med.21318 [published ahead of print] · DOI
- Silvano, 2010, The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors, Mol Pharmacol, 78, 925, 10.1124/mol.110.065755 · DOI
- Simon, 1975, Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions, Proc Natl Acad Sci USA, 72, 2404, 10.1073/pnas.72.6.2404 · DOI
- Smith, 2010, Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes, Pharmacol Rev, 62, 701, 10.1124/pr.110.002667 · DOI · Paper page
- Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR (2014) Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. DOI: 10.1016/j.pain.2014.06.011 [published ahead of print] · DOI · Paper page
- Spalding, 2002, Discovery of an ectopic activation site on the M(1) muscarinic receptor, Mol Pharmacol, 61, 1297, 10.1016/S0026-895X(24)12088-3 · DOI · Paper page
- Spedding, 1995, New drug binding sites in Ca2+ channels, Trends Pharmacol Sci, 16, 139, 10.1016/S0165-6147(00)89002-1 · doi:10.1016/s0165-6147(00)89002-1
- Spedding, 1987, Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand, Br J Pharmacol, 92, 457, 10.1111/j.1476-5381.1987.tb11343.x · doi:10.1111/j.1476-5381.1987.tb11343.x
- Stallaert, 2011, Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors, Expert Opin Drug Discov, 6, 811, 10.1517/17460441.2011.586691 · DOI
- Steinfeld, 2007, A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor, Mol Pharmacol, 72, 291, 10.1124/mol.106.033746 · DOI
- Sterin-Borda, 1999, Alterations in cardiac beta-adrenergic receptors in chagasic mice and their association with circulating beta-adrenoceptor-related autoantibodies, Cardiovasc Res, 41, 116, 10.1016/S0008-6363(98)00225-9 · doi:10.1016/s0008-6363(98)00225-9
- Stewart, 2010, Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae, Mol Pharmacol, 78, 205, 10.1124/mol.110.064253 · DOI
- Stockton, 1983, Modification of the binding properties of muscarinic receptors by gallamine, Mol Pharmacol, 23, 551, 10.1016/S0026-895X(25)14327-7 · DOI · Paper page
- Suratman, 2011, Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor, Br J Pharmacol, 162, 1659, 10.1111/j.1476-5381.2010.01184.x · DOI
- Swaminath, 2003, Identification of an allosteric binding site for Zn2+ on the β2 adrenergic receptor, J Biol Chem, 278, 352, 10.1074/jbc.M206424200 · DOI
- Swaminath, 2002, Allosteric modulation of β2-adrenergic receptor by Zn(2+), Mol Pharmacol, 61, 65, 10.1124/mol.61.1.65 · DOI
- Szabo, 2014, Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor, J Med Chem, 57, 4924, 10.1021/jm500457x · DOI
- Taly, 2009, Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system, Nat Rev Drug Discov, 8, 733, 10.1038/nrd2927 · DOI · Paper page
- Tan, 2013, Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex, Science, 341, 1387, 10.1126/science.1241475 · DOI · Paper page
- Thomas, 1997, Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide, Proc Natl Acad Sci USA, 94, 14115, 10.1073/pnas.94.25.14115 · DOI
- Thomas, 1998, Oleamide-induced modulation of 5-hydroxytryptamine receptor-mediated signaling, Ann N Y Acad Sci, 861, 183, 10.1111/j.1749-6632.1998.tb10190.x · DOI
- Thompson, 2008, G protein-coupled receptors disrupted in human genetic disease, Methods Mol Biol, 448, 109, 10.1007/978-1-59745-205-2_7 · DOI
- Tränkle, 1998, Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors, Mol Pharmacol, 54, 139, 10.1124/mol.54.1.139 · doi:10.1124/mol.54.1.139
- Tschammer, 2011, Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor, Mol Pharmacol, 79, 575, 10.1124/mol.110.068106 · DOI
- Tschammer, 2011, Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions, J Med Chem, 54, 2477, 10.1021/jm101639t · DOI
- Urban, 2007, Functional selectivity and classical concepts of quantitative pharmacology, J Pharmacol Exp Ther, 320, 1, 10.1124/jpet.106.104463 · DOI · Paper page
- Valant, 2012, Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor, J Med Chem, 55, 2367, 10.1021/jm201600e · DOI
- Valant, 2010, Delineating the mode of action of adenosine A1 receptor allosteric modulators, Mol Pharmacol, 78, 444, 10.1124/mol.110.064568 · DOI
- Valant, 2012, Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects, Mol Pharmacol, 81, 41, 10.1124/mol.111.074872 · DOI
- Valant, 2008, A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand, J Biol Chem, 283, 29312, 10.1074/jbc.M803801200 · DOI · Paper page
- Valant, 2014, Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist, Proc Natl Acad Sci USA, 111, 4614, 10.1073/pnas.1320962111 · DOI
- Valant, 2012, The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors, Annu Rev Pharmacol Toxicol, 52, 153, 10.1146/annurev-pharmtox-010611-134514 · DOI · Paper page
- Valant, 2009, Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs, Mol Interv, 9, 125, 10.1124/mi.9.3.6 · DOI
- Vallée, 2014, Pregnenolone can protect the brain from cannabis intoxication, Science, 343, 94, 10.1126/science.1243985 · DOI · Paper page
- van der Westhuizen, 2014, Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy, Mol Pharmacol, 85, 492, 10.1124/mol.113.088880 · DOI · Paper page
- Varney, 1999, SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5, J Pharmacol Exp Ther, 290, 170, 10.1016/S0022-3565(24)34881-5 · DOI · Paper page
- Verbout, 2007, Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism, Am J Physiol Lung Cell Mol Physiol, 292, L1126, 10.1152/ajplung.00455.2006 · DOI
- Violin, 2014, Biased ligands at G-protein-coupled receptors: promise and progress, Trends Pharmacol Sci, 35, 308, 10.1016/j.tips.2014.04.007 · DOI · Paper page
- Wang, 2014, Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs, Nature Comm, 5, 4355, 10.1038/ncomms5355 · DOI · Paper page
- Wenthur, 2014, Drugs for allosteric sites on receptors, Annu Rev Pharmacol Toxicol, 54, 165, 10.1146/annurev-pharmtox-010611-134525 · DOI · Paper page
- Williams, 1978, Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors, J Biol Chem, 253, 2984, 10.1016/S0021-9258(17)40792-7 · doi:10.1016/s0021-9258(17)40792-7
- Wootten, 2012, Allosteric modulation of endogenous metabolites as an avenue for drug discovery, Mol Pharmacol, 82, 281, 10.1124/mol.112.079319 · DOI
- Wu, 2014, Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator, Science, 344, 58, 10.1126/science.1249489 · DOI · Paper page
- Zhang, 2005, Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes, J Pharmacol Exp Ther, 315, 1212, 10.1124/jpet.105.090308 · DOI
Cited by
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
Common activation mechanism of class A GPCRs
Zhou, Q., Yang, D., Wu, M., Guo, Y., Guo, W., Zhong, L., Cai, X., Dai, A., Jang, W., Shakhnovich, E. I., et al. (2019) · eLife · doi:10.7554/elife.50279 · Cited by 632
Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation
Changeux, J.-P., & Christopoulos, A. (2016) · Cell · doi:10.1016/j.cell.2016.08.015 · Cited by 336
Self-citationIns and outs of GPCR signaling in primary cilia
Schou, K. B., Pedersen, L. B., & Christensen, S. T. (2015) · The EMBO Reports · doi:10.15252/embr.201540530 · Cited by 221
ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks
Shen, Q., Wang, G., Li, S., Liu, X., Lu, S., Chen, Z., Song, K., Yan, J., Geng, L., Huang, Z., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv902 · Cited by 122
Metadata
- Authors
- Christopoulos, A.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 86
- Issue
- 5
- Pages
- 463-478
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2050650917
- Cited by
- 220
- References
- 12
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in G Protein-Coupled Receptor Allostery: From Function to Structure. https://app.cochat.ai/papers/10.1124/mol.114.094342
- The paper
- Christopoulos, A. (2014). Advances in G Protein-Coupled Receptor Allostery: From Function to Structure. Molecular Pharmacology. https://doi.org/10.1124/mol.114.094342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.